• Johnson & Johnson initiates Pivotal Global Phase 3 Clinical Trial of Janssen’s COVID-19 vaccine candidate

    Thursday September 24th 2020

  • Camel-IDS enters next stage with name change to PRECIRIX® and IND approval for CAM-H2 Phase I/II study

    Tuesday September 22nd 2020

  • Primary endpoint achieved with ziritaxestat in NOVESA trial in systemic sclerosis patients

    Friday September 11th 2020

  • Oxurion NV reports first patient dosed in Phase 2 study evaluating THR-149 for treatment of Diabetic Macular Edema (DME)

    Tuesday September 1st 2020

  • Precigen ActoBio announces positive topline results from Phase 1b study of AG019 ActoBiotics

    Tuesday August 11th 2020

  • Mithra announces shelf life extension for Myring™ to 36 months

    Tuesday August 4th 2020

  • Gilead en Galapagos kondigen positieve Europese CHMP opinie aan voor Jyseleca® (Filgotinib) voor de behandeling van volwassenen met matige tot ernstige reumatoïde artritis

    Friday July 24th 2020

  • Aligos Therapeutics and KU Leuven announce collaboration for the development of a therapeutic candidate targeting Coronavirus

    Thursday July 2nd 2020

  • Your news here?

  • US multicenter study shows Idylla™ allows rapid and accurate mutation testing results across different laboratory settings

    Friday June 26th 2020

  • eTheRNA raises EUR 34 million in Series B financing to accelerate multiple mRNA therapeutic development programs through to clinical proof of concept

    Wednesday June 17th 2020

  • Johnson & Johnson announces acceleration of its COVID-19 vaccine candidate

    Thursday June 11th 2020


Strategic Partners